J&J to Acquire Ambrx, Boosting Oncology Pipeline with Next-Gen ADCs

TL;DR

**J&J is buying Ambrx to get its cutting-edge cancer drug technology, big play for future growth.**

AI Summary

Johnson & Johnson (JNJ) announced on January 8, 2024, its definitive agreement to acquire Ambrx Biopharma, Inc. (AMAM), a clinical-stage biopharmaceutical company. This acquisition aims to bolster Johnson & Johnson's oncology portfolio, specifically by integrating Ambrx's next-generation antibody drug conjugates (ADCs), including its lead product candidate ARX517, which targets prostate-specific membrane antigen (PSMA) for cancer treatment. This move is significant for investors as it signals Johnson & Johnson's strategic investment in innovative cancer therapies, potentially driving future growth and market share in the competitive pharmaceutical industry.

Why It Matters

This acquisition strengthens Johnson & Johnson's position in the lucrative oncology market, potentially leading to new revenue streams from advanced cancer treatments. It demonstrates J&J's commitment to innovation and growth in a key therapeutic area.

Risk Assessment

Risk Level: medium — While strategic, the success of the acquisition depends on the clinical and commercial success of Ambrx's drug candidates, which is inherently risky in biopharma.

Analyst Insight

A smart investor would view this acquisition as a positive strategic move for Johnson & Johnson, reinforcing its long-term growth prospects in oncology. It might be prudent to monitor the progress of Ambrx's drug candidates under J&J's management for future valuation impacts.

Key Players & Entities

• Johnson & Johnson (company) — acquiring company
• Ambrx Biopharma, Inc. (company) — acquired company
• ARX517 (person) — lead product candidate
• January 8, 2024 (person) — date of acquisition announcement
• Brian Kenney (person) — media contact for Johnson & Johnson
• Suzanne Frost (person) — media contact for Johnson & Johnson
• Raychel Kruper (person) — investor contact for Johnson & Johnson

Forward-Looking Statements

• Johnson & Johnson's oncology pipeline will see accelerated growth and innovation due to the integration of Ambrx's ADC technology. (Johnson & Johnson) — medium confidence, target: 2025-12-31
• Ambrx's lead candidate, ARX517, will progress further in clinical trials under Johnson & Johnson's ownership. (ARX517) — medium confidence, target: 2026-12-31

FAQ

From the Filing

0001193125-24-003957.txt : 20240108 0001193125-24-003957.hdr.sgml : 20240108 20240108082225 ACCESSION NUMBER: 0001193125-24-003957 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 24518474 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 DEFA14A 1 d653837ddefa14a.htm DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material under §240.14a-12 Ambrx Biopharma, Inc. (Name of Registrant as Specified In Its Charter) Johnson & Johnson (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. On January 8, 2024, Johnson & Johnson, a New Jersey corporation (the “Company”), issued the following press release in connection with the Company’s entry into a definitive agreement to acquire Ambrx Biopharma, Inc. Media contacts: Brian Kenney 215-620-0111 Suzanne Frost 416-317-0304 Investor contact: Raychel Kruper investor-relations@its.jnj.com For Immediate Release Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnson’s Commitment to Oncology Innovation Novel Technology Platform Sets Stage for the Development of Next Generation ADCs and Targeted Oncologic Therapeutics NEW BRUNSWICK, NJ (January 8, 2024) – Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety of its candidate therapeutics in multiple cancer indications, including ARX517, its proprietary ADC targeting PSMA for metastatic castration-resistant prostate cancer (mCRPC); ARX788, its proprietary ADC targeting human epidermal growth factor receptor 2 (HER2) for metastatic HER2+ breast cancer; and ARX305, its proprietary ADC targeting CD-70 for renal cell carcinoma. “Ambrx’s ADC technology offers unique advantages in the conjugation of stable antibodies and cytotoxic linker payloads, which results in engineered ADCs that effectively kill cancer cells and limit toxicities,” said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson